Kymera Therapeutics Inc
KYMR
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.7B
Close$
$-0.12
100.2% downside
Current Fair Value
100.2% downsideOvervalued by 100.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.70 Billion |
|---|---|
| Enterprise Value | $6.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.69 |
| Beta | 2.06 |
| Outstanding Shares | 97,534,269 |
Return
| Return on Equity | -20.46% |
|---|---|
| Return on Assets | -18.88% |
| Return on Invested Capital | -21.58% |
Valuation & Multiples
| P/E Ratio | -25.21 |
|---|---|
| PEG | -452.52 |
| Price to Sales | - |
| Price to Book Ratio | 4.88 |
| Enterprise Value to Revenue | 128.9 |
| Enterprise Value to EBIT | -19.14 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$8.27 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.70
Average shareholder expectationRevenue Estimate
$29.91 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0502▼ 93.40% |
|---|---|
| Total Calls | 113,500▲ 12.27% |
| Total Puts | 119,200▼ 40.58% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 114.10%▲ 11.16% |
|---|---|
| Total Invested | $8.01B▲ 14.61% |
| Investors Holding | 262▼ 1.00% |
ESG Score
No data
About Kymera Therapeutics Inc
75 employeesKymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted...